<--- Back to Details
First PageDocument Content
Gilead Sciences / HIV/AIDS / Pharmaceuticals policy / Bristol-Myers Squibb / Emtricitabine/tenofovir/efavirenz / AIDS / Medicare Part D / Tenofovir / Formulary / Health / Medicine / Pharmacology
Date: 2014-02-05 17:34:29
Gilead Sciences
HIV/AIDS
Pharmaceuticals policy
Bristol-Myers Squibb
Emtricitabine/tenofovir/efavirenz
AIDS
Medicare Part D
Tenofovir
Formulary
Health
Medicine
Pharmacology

Microsoft Word - FPC QHP Policy Guide Febdoc

Add to Reading List

Source URL: fairpricingcoalition.org

Download Document from Source Website

File Size: 175,69 KB

Share Document on Facebook

Similar Documents

Healthcare reform in the United States / Health / Federal assistance in the United States / Presidency of Lyndon B. Johnson / Managed care / Medicare / End Stage Renal Disease Program / Medicaid / Fee-for-service / Attachment theory

Announcement of Calendar Year (CYMedicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter and Request for Information

DocID: 1xTu9 - View Document

Medicare Part D stand-alone prescription drug plans for 2018 People who get their health benefits from a Medicare supplement policy or a non-managed care Medicare Advantage plan with no drug coverage may enroll in a stan

DocID: 1tPLN - View Document

Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing (OEI; 07/17)

DocID: 1ttzb - View Document

Mirror, Mirror on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs By Marc-André Gagnon, PhD.

DocID: 1th0B - View Document

Coalition of 26 Groups to Congress: Oppose Medicare Part D Rebate Proposals June 21, 2016 Dear Senators and Representatives: In the final months of the Obama Administration, the White House and Congress will engage in an

DocID: 1sahA - View Document